Thu . 20 Jul 2020
TR | RU | UK | KK | BE |

Giant-cell carcinoma of the lung

Giant-cell carcinoma of the lung GCCL is a rare histological form of large-cell lung carcinoma, a subtype of undifferentiated lung cancer, traditionally classified within the non-small-cell lung carcinomas NSCLC

The characteristic feature of this highly lethal malignancy is the distinctive light microscopic appearance of its extremely large cells, which are bizarre and highly pleomorphic, and which often contain more than one huge, misshapen, pleomorphic nucleus "syncytia", which result from cell fusion

Although it is common in the lung cancer literature to refer to histologically mixed tumors containing significant numbers of malignant giant cells as "giant-cell carcinomas", technically a diagnosis of "giant-cell carcinoma" should be limited strictly to neoplasms containing only malignant giant cells ie "pure" giant-cell carcinoma1

Aside from the great heterogeneity seen in lung cancers especially those occurring among tobacco smokers, the considerable variability in diagnostic and sampling techniques used in medical practice, the high relative proportion of individuals with suspected GCCL who do not undergo complete surgical resection, and the near-universal lack of complete sectioning and pathological examination of resected tumor specimens prevent high levels of quantitative accuracy


  • 1 Epidemiology
  • 2 Classification
  • 3 Microscopic features and cytology
  • 4 Tissue architectural features
  • 5 Macroscopic features
  • 6 Staining and immunohistochemistry
  • 7 Differential diagnosis
  • 8 Sites of metastasis
  • 9 Pathogenesis and genetics
  • 10 Combined/multiphasic tumors containing giant cells
  • 11 Imaging characteristics
  • 12 Positron emission tomography scanning
  • 13 Metabolic pathways
  • 14 Paraneoplastic syndromes
  • 15 Treatment
  • 16 Prognosis
  • 17 History
  • 18 References
  • 19 External links


The true incidence, prevalence, and mortality of GCCL is generally unknown due to a lack of accurate cancer data on a national level It is known to be a very rare tumor variant in all populations examined, however In an American study of a database of over 60,000 lung cancers, GCCL comprised between 03% and 04% of primary pulmonary malignancies, with an age-adjusted incidence rate of about 3 new cases per million persons per year2 With approximately 220,000 total lung cancers diagnosed in the US each year,3 the proportion suggests that approximately 660 and 880 new cases are diagnosed in Americans annually24

However, in a more recent series of 4,212 consecutive lung cancer cases, only one 0024% lesion was determined to be a "pure" giant-cell carcinoma after complete sectioning of all available tumor tissue5 While some evidence suggests GCCL may have been considerably more common several decades ago, with one series identifying 34% of all lung carcinomas as giant-cell malignancies,6 it is possible that this number reflect

Most published case series and reports on giant cell-containing lung cancers show that they are diagnosed much more frequently in men than they are in women,78 with some studies showing extremely high male-to-female ratios 12:1 or more In a study of over 150,000 lung cancer victims in the US, however, the gender ratio was just over 2:1, with women actually having a higher relative proportion of giant-cell cancers 04% than men 03%2

Giant-cell carcinomas have been reported to be diagnosed in a significantly younger population than all non-small-cell carcinomas considered as a group79 Like nearly all lung carcinomas, however, GCCs are exceedingly rare in very young people: in the US SEER program, only 2 cases were recorded to occur in persons younger than 30 years of age between 1983 and 19872 The average age at diagnosis of these tumors has been estimated at 60 years7

The vast majority of individuals with GCCL are heavy smokers7

Although the definitions of "central" and "peripheral" can vary7 between studies, GCCL are consistently diagnosed much more frequently in the lung periphery7 In a review of literature compiled by Kallenburg and co-workers, less than 30% of GCCLs arose in the hilum or other parts of the "central" pulmonary tree9

A significant predilection for genesis of GCCL in the upper lobes of victims has also been postulated7


For several decades, primary lung cancers were consistently dichotomously classified for treatment and research purposes into small-cell lung carcinomas SCLCs and non-small-cell lung carcinomas NSCLCs, based on an oversimplified approach that is now clearly outmoded The new paradigm recognizes that lung cancers are a large and extremely heterogeneous family of malignant neoplasms,10 with over 50 different histological variants included in the 4th 2004 revision of the World Health Organization typing system, the most widely used lung cancer classification scheme "WHO-2004"1 These variants are increasingly appreciated as having different genetic, biological, and clinical properties, including prognoses and responses to treatment regimens, and therefore, that correct and consistent histological classification of lung cancers are necessary to validate and implement optimum management strategies1112

About 1% of lung cancers are sarcomas, germ cell tumors, and hematopoietic tumors, while 99% of lung cancers are carcinoma Carcinomas are tumors composed of transformed, abnormal cells with epithelial tissue architecture and/or molecular characteristics, and which derive from embryonic endoderm2 Eight major taxa of lung carcinomas are recognized within the WHO-2004 classification:1

  1. Small-cell carcinoma
  2. Squamous cell carcinoma
  3. Adenocarcinoma
  4. Large-cell carcinoma
  5. Adenosquamous carcinoma
  6. Sarcomatoid carcinoma
  7. Carcinoid
  8. Salivary gland-like carcinoma

The subclassification of GCCL among these major taxa has undergone significant changes in recent decades Under the 2nd revision 1981 of the WHO classification, it was considered a subtype of large-cell carcinoma13 In the 3rd 1999 revision,14 it was placed within a taxon called "Carcinomas with Pleomorphic, Sarcomatoid, or Sarcomatous Elements", along with pleomorphic carcinoma, spindle cell carcinoma, carcinosarcoma, and pulmonary blastoma, which are arguably related variants While the 4th revision "WHO-2004" retained the same grouping of lesions as the 3rd revision, the name of the major taxon was shortened to "sarcomatoid carcinomas"1

The current rules for classifying lung cancers under WHO-2004, while useful and improved, remain to some extent fairly complex, ambiguous, arbitrary, and incomplete1 Although it is fairly common for mixed tumors that are seen to contain malignant giant cells to be called "giant-cell carcinomas", accurate classification of a pulmonary tumor as a GCCL requires that the entire tumor consists only of malignant giant cells Therefore, complete sampling of the entire tumor — obtained via a surgical resection — is absolutely necessary for a definitive diagnosis of GCCL to be made1

Microscopic features and cytologyedit

The background contained numerous lymphocytes and neutrophils The shape of the tumor cell was spindle or pleomorphic, and the sizes of the tumor cells varied by more than 5-fold The tumor cells had an abundant, thick and well-demarcated cytoplasm The location of the nucleus was centrifugal, and the nucleus was oval or irregularly shaped Multinucleated giant cells were frequently observed The size of the nucleus was more than 5 times that of normal lymphocytes, and its size also varied by more than 5-fold The nuclear membrane was thin, and nuclear chromatin was coarsely granular, while the nucleolus was single and round

In cytological preparations, giant cells typically appear as single cells or in flat loose clusters, and occasionally in fascicles15

GCCL are considered a member of the most common type of lung cancer, called "non-small-cell carcinomas" This group of lethal neoplasms make up approximately 85% of all lung cancers1 By the definition of "large-vs-small-cell carcinoma", the diameter of GCCL cells must be considerably greater than three times that of a resting ie unstimulated lymphocyte Also by definition, GCCL do not contain any amount of these small, neurosecretory granule-containing, neuroendocrine cells that are characteristic of small-cell carcinomas — when they do, the tumor should be classified as a combined small-cell carcinoma1

Compared to most other lung cancer variants, cells comprising GCCL tend to be much larger up to 150 micrometers diameter, or even larger,16 Both cells and nuclei show extreme variation in size distribution and shape Carcinomatous giant cells carcinoma nuclei have been reported to average 5 times the size of lymphocyte nuclei15

The cells from giant-cell carcinomas are anaplastic, and show no evidence of cell maturation or differentiation, lacking the cytological and tissue architectural characteristics of squamous cell carcinoma, adenocarcinoma, neuroendocrine carcinomas, or other more differentiated lung cancer cell types They tend to be highly pleomorphic ie variable in characteristics, but are most often round and/or polygonal in shape, with a relatively low nuclear-to-cytoplasmic ratio When associated with spindle cells, as they very frequently are in tumors with mixed histology, malignant giant cells tend to form loosely cohesive aggregate structures on cytological examination However, when a biopsy sample consists purely of malignant giant cells, the cells tend to be single and disaggregated1

Case series suggest that the relative number of giant cells in a given tumor are generally directly proportional to the size of the tumor, and to the relative amount of necrosis17

Giant cells in a lung cancer are highly associated with the presence of spindle cells18

The chromatin of malignant giant cells tends to be hyperchromatic and coarsely clumped Nucleoli are usually multiple and prominent16

Subcellular characteristics often noted in the malignant giant cells of GCCL cases include abundant mitochondria, concentric whorls of tonofilament-like fibrils, and aggregates of several pairs of centrioles19

Both "tumor cell-tumor cell" and "leukocyte-tumor cell" emperipolesis ie active penetration of the latter by the former is very commonly seen in cases of GCCL19

Tissue architectural featuresedit

In mixed tumors, giant cells are more likely to be found in higher proportions at the edge of a tumor18 When extensive necrosis is present, it is possible for a giant-cell tumor to have only a thin rim of viable cells remaining at the perimeter of the mass

In one early case series, abundant production of loose malignant giant cells were noted to fill the alveoli of victims without destroying, infiltrating, or disturbing the normal underlying architecture, a pathologic behavior that bears some resemblance to the pneumonic variant of bronchioloalveolar carcinoma20

Extensive tumor necrosis and hemorrhage is extremely common in GCCL20

Although the issue has not been extensively studied in a controlled fashion, GCCLs have been noted to contain significantly elevated levels of VEGF21 However, in one study where a giant-cell carcinoma tumor that had been completely excised was sectioned and examined, no qualitative or quantitative abnormalities in tissue vascularization were noted16

GCCL have been noted to be encapsulated, and to be divided via septa into "pseudolobules", by a highly fibrous stroma, suggested to be produced commensurately with tumor growth The capsule is typically infiltrated with malignant giant cells22

Macroscopic featuresedit

Giant-cell carcinomas of the lung frequently show extensive necrosis22 and myxoid degeneration18

A trend toward less vascularity and tissue density with lower contrast enhancement on CT has been noted toward the center of these lesions, especially in larger tumors, and even in tumors without a significant volume of gross necrosis7

Grossly, the cut surfaces of these malignancies are often gray-white or tan, and frequently show myxoid, necrotic, and/or hemorrhagic foci7 These sorts of areas often show low levels of contrast enhancement on CT scanning

Low encapsularity and high levels of tissue collagen tend to be observed, with high contrast enhancement in these areas7

GCCL have been seen to develop from/in emphysematous bullae23

Staining and immunohistochemistryedit

A case of a brain metastasis from a giant-cell lung carcinoma both "pure" tested positive for cytokeratins AE1/AE3, and negative for CK-7, CK-20, TTF-1, and GFAP24

GCCL cells often stain intensely by Periodic acid-Schiff reagent, suggesting the presence of significant amounts of glycogen in the cell cytoplasm22

Differential diagnosisedit

Under light microscopy, the giant malignant pleomorphic cells making up a GCCL resemble those found in choriocarcinoma,1 angiosarcoma,25 and some forms of true sarcoma,1 such as malignant fibrous histiocytoma1 and rhabdomyosarcoma16 In some instances, they can also bear considerable resemblance to "activated" histiocytes seen in some inflammatory conditions16

A rare and potentially difficult differential diagnostic dilemma occurs when GCCLs must be separated from pulmonary or mediastinal choriocarcinomas, a critical distinction to me made because while there is a known standard of care for treating choriocarcinoma, as yet there is no generally accepted specific standard treatment for GCCL Careful review of cell morphology is key to their delineation — while GCCLs show great variation in cell size distributions and morphologies in tumors, choriocarcinomas consistently contain only syncytiotrophoblasts and cytotrophoblasts26 GCCL and primary pulmonary choriocarcinoma can also be differentiated on the basis of ultrastructural features by electron microscopy, although EM is not yet widely applicable27

Occasionally, a bone metastasis of a GCCL could potentially be mistaken for a primary giant-cell tumor of bone28 — interestingly, the latter entity can behave as a neoplasm of benign, frankly malignant,29 or borderline30 in its clinical behavior31

Sites of metastasisedit

GCCLs are particularly notable among lung cancers for their extremely unusual tendency to metastasize to the small intestine, occasionally causing obstruction, severe bleeding, and/or intussusception This clinical characteristic of GCCL has been seen in cases spanning over half a century in time3233

Within the small bowel, the jejunum seems to be a preferred site for metastasis of GCCL

GCCL also often metastasizes to bone,28 adrenal, brain,24 lung, liver, kidney,

Brain metastases from GCCL are particularly likely to cause significant cerebral hemorrhages as compared to other lung cancer variants, probably due to greatly increased rates of endothelial proliferation and neovascularization, tumor tissue growth, extensive necrosis, and aggressive local infiltrative character of GCCL cells24

Pathogenesis and geneticsedit

Several studies, both in giant-cell tumor specimens and in cell lines, have identified rearrangement and amplification of the c-myc oncogene, sometimes in combination with mutations of the K-ras gene3435

Overexpression of vascular endothelial growth factor VEGF has been shown to occur in GCCL and is thought to be related to the high metastatic potential of this lung cancer variant21

Malignant giant cells identical to those found in GCCL commonly occur in lung cancer cases with a prominent major or minor clear-cell carcinoma pattern for a discussion about this variant, see for example36 They have been hypothesized to derive from an undifferentiated multipotent malignant stem cell precursor that is generated in distal bronchioles via an as yet unknown oncogenetic pathway or oncogenetic driver19

Ultrastructurally, malignant giant cells often contain accumulations of microfilaments arranged in whorls near the cell nucleus These entities appear similar in structure to microfilaments and bundles found in the D1 cell of the gastro-entero-pancreatic endocrine system, and it has been proposed that these D1 cells may be the cancer stem cell for at least some GCCLs Identically appearing whorled filament structures have also been produced in certain airway cells of animals after treatment with carcinogenic nitrosamines37

Ultrastructural studies have suggested that the malignant giant cells in GCCL are of endodermal lineage38

Remarkably fast growing tumors24

Combined/multiphasic tumors containing giant cellsedit

Malignant giant cells are commonly found — and vary in relative proportion to a greater or lesser degree — in both primary tumors and metastatases of many different variants of lung carcinomas A number of authors have noted that bizarre malignant giant cells occur more commonly in primary and secondary tumors — including any remaining tumor "deposits" — that have previously been treated with chemotherapy and/or radiation therapy in adjuvant or neoadjuvant protocols38

Imaging characteristicsedit

GCCL often presents as a large peripheral mass that is severely cavitated39

In a radiographic study of almost 2,000 lung cancer patients published 50 years ago, 34% of lung carcinomas proved to be cavitated masses,40 most of which were squamous cell carcinoma

In a number of cases of severe cavitation, the resected tumor remnant consists of only a thin rim of proliferating cells

Positron emission tomography scanningedit

On positron emission tomography PET scanning, GCCL has been found to have exceedingly high standardized uptake values SUV for radioactive glucose, values that are statistically significantly higher than in other histological variants of lung cancer5

Metabolic pathwaysedit

PET scanning suggests that GCCL are tumors with particularly rapid metabolism, and that the metabolic pathways of GCCL may be unusually dependent on, or interlinked to, glycolysis5

Paraneoplastic syndromesedit

GCCL have been long known41 for secretion of the beta subunit of human chorionic gonadotropin beta-HCG, often in large amounts, which can lead to very high levels of estrogen and painful gynecomastia breast enlargement in males as paraneoplastic signs42

Giant-cell lung cancers are well known for their paraneoplastic production and secretion of granulopoietic colony stimulating factor G-CSF3543

GCCL has also been reported to produce plasminogen activator as a paraneoplastic phenomenon16


Because of its rarity, there have been no randomized clinical trials of treatment of GCCL, and all information available derives from small retrospective institutional series or multicenter metadata44


Giant-cell lung cancers have long been considered to be exceptionally aggressive malignancies92245 that grow very rapidly35 and have a very poor prognosis8

Many small series have suggested that the prognosis of lung tumors with giant cells is worse than that of most other forms of non-small-cell lung cancer NSCLC,18 including squamous cell carcinoma,8 and spindle cell carcinoma8

The overall five-year survival rate in GCCL varies between studies but is generally considered to be very low The US Armed Forces Institute of Pathology has reported a figure of 10%,46 and in a study examining over 150,000 lung cancer cases, a figure of 118% was given2 However, in the latter report the 118% figure was based on data that included spindle cell carcinoma, a variant which is generally considered to have a less dismal prognosis than GCCL18 Therefore, the likely survival of "pure" GCCL is probably lower than the stated figure

In the large 1995 database review by Travis and colleagues, giant-cell carcinoma has the third-worst prognosis among 18 histological forms of lung cancer Only small-cell carcinoma and large-cell carcinoma had shorter average survival2

Most GCCL have already grown and invaded locally and/or regionally, and/or have already metastasized distantly, and are inoperable, at the time of diagnosis22


Most sources credit Nash and Stout with publishing the first detailed report in the medical literature recognizing GCCL as a distinct clinicopathological entity in 195847 However, there is some evidence that suggests this tumor phenotype was described as early as 195120 In a report on 3 cases of giant-cell lung carcinoma published in 1961 by ZM Naib, the author cites 2 previous studies related to GCCL — one published in 1951 by MM Patton and co-workers,48 and one published in 1955 by Walton and Pryce49 In 1969, Dr Alexander Kennedy, in a case series of 3 GCCL Kennedy published in 1969,22 credited Hadley and Bullock with the first usage of the term "giant-cell carcinoma" 16 years prior50

GCCL was first confirmed as an epithelial tumor and not a dedifferentiated pleomorphic sarcoma in 196151 In 1964–65, theories were postulated that GCCLs were dediffentiated adenocarcinomas52 and, in some cases, were thought to derive from clear-cell adenocarcinomas36


  1. ^ a b c d e f g h i j k l Travis, William D; Brambilla, Elisabeth; Muller-Hermelink, H Konrad; et al, eds 2004 Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart PDF World Health Organization Classification of Tumours Lyon: IARC Press ISBN 92-832-2418-3 Retrieved 27 March 2010 
  2. ^ a b c d e f g Travis WD, Travis LB, DeVesa SS 1995 "Lung Cancer" Cancer 75: 191–202 PMID 8000996 doi:101002/1097-01421995010175:1+<191::AID-CNCR2820751307>30CO;2-Y 
  3. ^ "Fact Sheet: Cancer of the Lung and Bronchus" National Cancer Institute, SEER Program Retrieved February 24, 2012 
  4. ^ Martin LW, Correa AM, Ordonez NG, et al September 2007 "Sarcomatoid carcinoma of the lung: a predictor of poor prognosis" Ann Thorac Surg 84 3: 973–80 PMID 17720411 doi:101016/jathoracsur200703099  <!- Page given was 981 ->
  5. ^ a b c Park JS, Lee Y, Han J, et al 2011 "Clinicopathologic outcomes of curative resection for sarcomatoid carcinoma of the lung" Oncology 81 3-4: 206–13 PMID 22076573 doi:101159/000333095 
  6. ^ Hellstrom HR, Fisher ER 1963 "Giant cell carcinoma of lung" Cancer 16: 1080–8 PMID 14050012 doi:101002/1097-014219630816:8<1080::aid-cncr2820160816>30co;2-v 
  7. ^ a b c d e f g h i j Kim TH, Kim SJ, Ryu YH, et al August 2004 "Pleomorphic carcinoma of lung: comparison of CT features and pathologic findings" Radiology 232 2: 554–9 PMID 15215543 doi:101148/radiol2322031201 
  8. ^ a b c d Zhao ZL, Song N, Huang QY, Liu YP, Zhao HR February 2007 "Clinicopathologic features of lung pleomorphic spindle/giant cell carcinoma—a report of 17 cases" Clinicopathologic features of lung pleomorphic spindle/giant cell carcinoma—a report of 17 cases Ai Zheng in Chinese 26 2: 183–8 PMID 17298750  Chinese text
  9. ^ a b c Kallenberg F, Jaqué J 1979 "Giant cell carcinoma of the lung Clinical and pathological assessment Comparison with other large-cell anaplastic bronchogenic carcinomas" Scand J Thorac Cardiovasc Surg 13 3: 343–6 PMID 542838 doi:103109/14017437909100576 
  10. ^ Roggli VL, Vollmer RT, Greenberg SD, McGavran MH, Spjut HJ, Yesner R 1985 "Lung cancer heterogeneity: a blinded and randomized study of 100 consecutive cases" Hum Pathol 16: 569–79 PMID 2987102 doi:101016/s0046-81778580106-4 
  11. ^ Rossi G, Marchioni A, Sartori1 G, Longo L, Piccinini S, Cavazza A 2007 "Histotype in non-small-cell lung cancer therapy and staging: The emerging role of an old and underrated factor" Curr Resp Med Rev 3: 69–77 doi:102174/157339807779941820 CS1 maint: Multiple names: authors list link
  12. ^ Vincent MD 2009 "Optimizing the management of advanced non-small-cell lung cancer: a personal view" Curr Oncol 16: 9–21 PMC 2722061  PMID 19672420 doi:103747/cov16i4465 
  13. ^ World Health Organization 1981 Histological typing of Lung Tumours 2nd ed Geneva: World Health Organization 
  14. ^ Brambilla E, Travis WD, Colby TV, Corrin B, Shimosato Y December 2001 "The new World Health Organization classification of lung tumours" Eur Respir J 18 6: 1059–68 PMID 11829087 doi:101183/090319360100275301 
  15. ^ a b Hiroshima K, Dosaka-Akita H, Usuda K, et al 2011 "Cytological characteristics of pulmonary pleomorphic and giant-cell carcinomas" Acta Cytol 55 2: 173–9 PMID 21325803 doi:101159/000320860 
  16. ^ a b c d e f Davidson JF, McNicol GP, Frank GL, Anderson TJ, Douglas AS January 1969 "Plasminogen-activator-producing tumour" Br Med J 1 5636: 88–91 PMC 1982019  PMID 5761832 doi:101136/bmj1563688 
  17. ^ Cacić M, Oberman B, Dvornik G December 1989 "Investigation of the applicability of histological classification of bronchial carcinoma according to the World Health Organization" Tumori 75 6: 580–2 PMID 2482566 CS1 maint: Multiple names: authors list link
  18. ^ a b c d e Matsui K, Kitagawa M May 1991 "Spindle cell carcinoma of the lung A clinicopathologic study of three cases" Cancer 67 9: 2361–7 PMID 1707339 doi:101002/1097-01421991050167:9<2361::aid-cncr2820670925>30co;2-3 
  19. ^ a b c Wang NS, Seemayer TA, Ahmed MN, Knaack J January 1976 "Giant cell carcinoma of the lung A light and electron microscopic study" Hum Pathol 7 1: 3–16 PMID 172430 doi:101016/s0046-81777680003-2 
  20. ^ a b c Naib ZM 1961 "Giant cell carcinoma of the lung: cytological study of the exfoliated cells in sputa and bronchial washings" Dis Chest 40: 69–73 doi:101378/chest40169 
  21. ^ a b Jiang DF, Lu YL, Qiu ZY, et al 2003 "Study of differential expression of molecules affecting the metastatic potential between highly and poorly metastatic human lung giant cell carcinoma" Zhonghua Zhong Liu Za Zai 25: 131–4 
  22. ^ a b c d e f Kennedy A May 1969 "Pathology and survival in operable cases of giant-cell carcinoma of the lung" J Clin Pathol 22 3: 354–60 PMC 474089  PMID 5784984 doi:101136/jcp223354 
  23. ^ Shirakusa T, Shigematsu N, Koga T, Yamagata Y 1980 "Giant cell carcinoma arising in a pulmonary bulla" Scand J Thorac Cardiovasc Surg 14 3: 307–9 PMID 7221506 doi:103109/14017438009101017 
  24. ^ a b c d Hagihara N, Abe T, Wakamiya T, Sugita Y, Watanabe M, Tabuchi K 2010 "A case of brain metastasis from pulmonary giant cell carcinoma" Kurume Med J 57 1-2: 39–41 PMID 21727764 doi:102739/kurumemedj5739 
  25. ^ Spivach A, Borea B, Bertoli G, Daris G July 1976 "Primary lung neoplasm of rare incidence: giant cell carcinoma" Minerva Med in Italian 67 34: 2233–49 PMID 986035 
  26. ^ Travis WD November 2010 "Sarcomatoid neoplasms of the lung and pleura" Arch Pathol Lab Med 134 11: 1645–58 PMID 21043818 doi:101043/2010-0086-RAR1 
  27. ^ Hayakawa K, Takahashi M, Sasaki K, Kawaoi A, Okano T January 1977 "Primary choriocarcinoma of the lung: case report of two male subjects" Acta Pathol Jpn 27 1: 123–35 PMID 557868 
  28. ^ a b Willebrand H, Wernitsch W, Elmohamed A September 1970 "Pulmonary metastases of a giant-cell carcinoma in the bone—benign or malignant" Chirurg in German 41 9: 419–23 PMID 5471024 
  29. ^ Huang L, Xu J, Wood DJ, Zheng MH March 2000 "Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation" Am J Pathol 156 3: 761–7 PMC 1876848  PMID 10702390 doi:101016/s0002-94401064942-5 
  30. ^ Werner M December 2006 "Giant cell tumour of bone: morphological, biological and histogenetical aspects" Int Orthop 30 6: 484–9 PMC 3172738  PMID 17013643 doi:101007/s00264-006-0215-7 
  31. ^ Pai SB, Lalitha RM, Prasad K, Rao SG, Harish K September 2005 "Giant cell tumor of the temporal bone—a case report" BMC Ear Nose Throat Disord 5: 8 PMC 1253509  PMID 16162299 doi:101186/1472-6815-5-8 
  32. ^ Thomas C 1962 "Giant cell carcinoma of the lungs" Frankf Z Pathol in German 72: 302–8 PMID 13981042 
  33. ^ Wellmann KF, Chafiian Y, Edelman E February 1969 "Small bowel perforation from solitary metastasis of clinically undetected pulmonary giant cell carcinoma" Am J Gastroenterol 51 2: 145–50 PMID 5776147 
  34. ^ Le Doussal JM, Gruaz-Guyon A, Martin M, Gautherot E, Delaage M, Barbet J June 1990 "Targeting of indium 111-labeled bivalent hapten to human melanoma mediated by bispecific monoclonal antibody conjugates: imaging of tumors hosted in nude mice" Cancer Res 50 11: 3445–52 PMID 2334941 
  35. ^ a b c Taya Y, Hosogai K, Hirohashi S, et al December 1984 "A novel combination of K-ras and myc amplification accompanied by point mutational activation of K-ras in a human lung cancer" EMBO J 3 12: 2943–6 PMC 557793  PMID 6098458 
  36. ^ a b Morgan AD, Mackenzie DH January 1964 "Clear-cell Carcinoma of the Lung" J Pathol Bacteriol 87: 25–7 PMID 14106350 doi:101002/path1700870104 
  37. ^ Carstens PH, Broghamer WL April 1978 "Duodenal carcinoid with cytoplasmic whorls of microfilaments" J Pathol 124 4: 235–8 PMID 569192 doi:101002/path1711240408 
  38. ^ a b Sidhu GS July 1979 "The endodermal origin of digestive and respiratory tract APUD cells Histopathologic evidence and a review of the literature" Am J Pathol 96 1: 5–20 PMC 2042351  PMID 37740 
  39. ^ Culiner MM, Abouav J, Reich SB November 1958 "Cavitary carcinoma of the lung" Calif Med 89 5: 355–8 PMC 1512515  PMID 13585165 
  40. ^ Strang C, Simpson JA March 1953 "Carcinomatous abscess of the lung" Thorax 8 1: 11–26 PMC 1019223  PMID 13038734 doi:101136/thx8111 
  41. ^ Dailey JE, Marcuse PM August 1969 "Gonadotropin secreting giant cell carcinoma of the lung" Cancer 24 2: 388–96 PMID 5796783 doi:101002/1097-014219690824:2<388::aid-cncr2820240222>30co;2-7 
  42. ^ Yaturu S, Harrara E, Nopajaroonsri C, Singal R, Gill S 2003 "Gynecomastia attributable to a human chorionic gonadotropin-secreting giant cell carcinoma of the lung" Endocr Pract 9 3: 231–5 PMID 12917067 
  43. ^ Kameda T; Kodama T; Shimosato Y 1982 Shimosato Y; Melamed MR; Nettesheim P, eds Morphogenesis of Lung Cancer 2 Boca Raton, Florida: CRC Press pp 107–29 
  44. ^ Bae HM, Min HS, Lee SH, Kim DW, Chung DH, Lee JS, Kim YW, Heo DS October 2007 "Palliative chemotherapy for pulmonary pleomorphic carcinoma" Lung Cancer 58 1: 112–5 PMID 17574296 doi:101016/jlungcan200705006 
  45. ^ Razzuk MA, Urschel HC, Albers JE, Martin JA, Paulson DL June 1976 "Pulmonary giant cell carcinoma" Ann Thorac Surg 21 6: 540–5 PMID 1275605 doi:101016/s0003-49751063926-4 
  46. ^ Colby TV, Koss MN, Travis WD 1995 "Tumors of the lower respiratory tract" In Rosai J, Sobin LH Atlas of Tumor Pathology Washington DC: Armed Forces Institute of Pathology pp 259–75 
  47. ^ Nash AD, Stout AP 1958 "Giant cell carcinoma of the lung; report of 5 cases" Cancer 11: 369–76 doi:101002/1097-0142195803/0411:2<369::aid-cncr2820110222>30co;2-8 
  48. ^ Patton MM, McDonald JR, Moersch HJ 1951 "Bronchogenic large cell carcinoma" J Thorac Cardiovasc Surg 22: 88 
  49. ^ Walter JB, Pryce DM June 1955 "The histology of lung cancer" Thorax 10 2: 107–16 PMC 1019475  PMID 14396845 doi:101136/thx102107 
  50. ^ Hadley GG, Bullock WK December 1953 "Autopsy reports of pulmonary carcinoma; survey in Los Angeles County Hospital for 1951" Calif Med 79 6: 431–3 PMC 1521859  PMID 13106728 
  51. ^ Ozzello L, Stout AP 1961 "The epithelial origin of giant cell carcinoma of the lung confirmed by tissue culture Report of a case" Cancer 14: 1052–6 PMID 13731858 doi:101002/1097-0142196109/1014:5<1052::aid-cncr2820140521>30co;2-d 
  52. ^ Friedberg EC February 1965 "Giant-Cell Carcinoma of the Lung: A dedifferentiated Adenocarcinoma" Cancer 18: 259–64 PMID 14254083 doi:101002/1097-014219650218:2<259::aid-cncr2820180219>30co;2-f 

External linksedit

  • "Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart" World Health Organization Classification of Tumours  Download Page
  • "Lung cancer page" National Cancer Institute 

Giant-cell carcinoma of the lung Information about

Giant-cell carcinoma of the lung

  • user icon

    Giant-cell carcinoma of the lung beatiful post thanks!


Giant-cell carcinoma of the lung
Giant-cell carcinoma of the lung
Giant-cell carcinoma of the lung viewing the topic.
Giant-cell carcinoma of the lung what, Giant-cell carcinoma of the lung who, Giant-cell carcinoma of the lung explanation

There are excerpts from wikipedia on this article and video

Random Posts

IP address blocking

IP address blocking

IP address blocking prevents connection between a server or website and certain IP addresses or rang...
Gisele Bündchen

Gisele Bündchen

Gisele Caroline Bündchen1 Portuguese pronunciation: ʒiˈzɛli kaɾoˈlini ˈbĩtʃẽj, German pronuncia...
Sheldon, West Midlands

Sheldon, West Midlands

Sheldon is an area of east Birmingham, England Historically part of Warwickshire, it is close to the...
Beverly, Chicago

Beverly, Chicago

Beverly is one of the 77 community areas of Chicago, Illinois It is located on the South Side on the...